Adeno-associated viruses (AAVs) are as small, replication-defective, non-enveloped viruses, serving as vectors for gene therapy. AAV vectors play a transformative role in delivering therapeutic genes ...
Many viral vectors have shown promise as gene delivery systems in small-animal studies 1. As these vectors progress to the next level of phase I and phase II clinical studies, it is important to ...
Adeno-associated virus (AAV) capsids are an effective mechanism for delivering gene therapies intended for therapeutic use. A critical production step is the separation of full capsids from empty ones ...
LOWER GWYNEDD, Pa.--(BUSINESS WIRE)--ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M ...
The main barrier in the progress of clinical gene therapy is the absence of a safe and efficient vector system with regulatable and tissue-specific characteristics. However, progress has been made in ...
With an adeno-associated virus (AAV)-based product now licensed by the U.S. Food and Drug Administration for treatment of spinal muscular atrophy in newborns, the race is on to fully exploit AAV-based ...
Adeno-associated viruses (AAVs) have emerged in recent years as a crucial tool in clinical gene therapies, offering low pathogenicity and long-lived gene expression in target cells. AAVs are simple ...
Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production. Certain additives or a ...
Waters Corporation’s XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies. Waters Corporation’s XBridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results